PedAM
Pediatric Disease Annotations & Medicines
| Disease | hyperglycemia |
| Phenotype | |type 2 diabetes |
| Sentences | 186 |
| PubMedID- 22837924 | [3] our study set out to estimate the prevalence and correlates of postprandial hyperglycemia in patients with type 2 diabetes and also to identify patients with isolated postprandial hyperglycemia, who are presumed to have optimal glycemic control. |
| PubMedID- 21074073 | The pharmacological treatment of hyperglycemia in type 2 diabetes should be individualized. |
| PubMedID- 22154739 | We hypothesized that et-1-induced vasoconstriction is augmented in type 2 diabetes with hyperglycemia through an increment in advanced glycation end-products (ages). |
| PubMedID- 24068868 | Perhaps it is not by chance that the position statement from the american diabetes association/european association for the study of diabetes (ada/easd) on the management of hyperglycemia in type 2 diabetes is subtitled ‘a patient-centered approach’.4 this statement highlights the clinical judgment (a mixture of clinical experience, knowledge, and skill) of physicians together with the patients’ values and preferences. |
| PubMedID- 23397557 | Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the american diabetes association (ada) and the european association for the study of diabetes (easd). |
| PubMedID- 23415113 | Dapagliflozin, a highly selective inhibitor of sglt2, has demonstrated efficacy, alone or in combination with metformin, in reducing hyperglycemia in patients with type 2 diabetes [35,36]. |
| PubMedID- 22611498 | Endothelial dysfunction associated with insulin resistance appears to precede the development of overt hyperglycemia in patients with type 2 diabetes mellitus [100, 101]. |
| PubMedID- 20130740 | Therefore, these results suggest that hps3 may partly ameliorate hyperglycemia and hyperlipidemia associated with type 2 diabetes through increased insulin secretion, inhibition of lipid peroxidation, promotion of sensitivity to insulin, suppression of gluconeogenesis and reduction in the biosynthesis fatty acid, cholesterol and cell cytokines related to insulin resistance, and it could be a useful adjunct therapy to a proven first-line therapy for type 2 diabetes using metformin. |
| PubMedID- 23199039 | Evidence is also available indicating that endothelial dysfunction precedes the development of overt hyperglycemia in patients with type 2 diabetes [15]. |
| PubMedID- 25813264 | Empagliflozin is a new medicine used to reduce hyperglycemia in patients with type 2 diabetes. |
| PubMedID- 21376312 | [recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes]. |
| PubMedID- 22933109 | hyperglycemia in type 2 diabetes is mediated by insulin resistance and β-cell failure, the latter leading to inadequate insulin secretion relative to the degree of insulin resistance. |
| PubMedID- 23264422 | For more details on pharmacotherapy for hyperglycemia in type 2 diabetes, including a table of information about currently approved classes of medications for treating hyperglycemia in type 2 diabetes, readers are referred to the ada-easd position statement (111). |
| PubMedID- 23880900 | When starting bedtime insulin in type 2 diabetes patients, those with fasting type hyperglycemia are prone to greater weight gain. |
| PubMedID- 24454371 | Our study showed that fasting hyperglycemia, mostly associated with type 2 diabetes, was the only significant predictor of vascular calcifications in esrd patients. |
| PubMedID- 26317347 | Agonist-induced activation of pparγ has been demonstrated to increase insulin sensitivity [25, 26] and thiazolidinediones (tzd) are used clinically to reduce insulin resistance and hyperglycemia in patients with type 2 diabetes, although these drugs are also associated with weight gain [27–31]. |
| PubMedID- 21304897 | hyperglycemia in type 2 diabetes is characterized by enhanced glucose production in the liver and kidney. |
| PubMedID- 21437084 | Good glycemic control is generally considered to be a glycated hemoglobin (hba1c) level of < 7.0%8 or < 6.5%,1,9 but there is increasing emphasis on separate fasting and postprandial plasma glucose targets.9–11 a combination of lifestyle advice (diet and exercise) and metformin is commonly recommended as a first-line therapy for the management of hyperglycemia for patients with type 2 diabetes.8,9 weight loss and increased activity, the goals of lifestyle advice, are associated with significant short- and long-term benefits, and thus form an important part of the therapeutic strategy throughout the course of the disease. |
| PubMedID- 24588941 | Due to their longer exposure to hyperglycemia, patients with young‒onset type 2 diabetes are at an increased risk of developing diabetes related complications. |
| PubMedID- 23584372 | type 2 diabetes consists of progressive hyperglycemia, insulin resistance, and pancreatic beta-cell failure which could result from glucose toxicity, inflammatory cytokines, and oxidative stress. |
| PubMedID- 22912709 | Background: chronic hyperglycemia in type 2 diabetes increases the risk of microvascular events. |
| PubMedID- 23949906 | The american diabetes association’s (ada) position statement on a patient-centered approach to the management of hyperglycemia in type 2 diabetes recommends that “if a patient presents with significant hyperglycemic symptoms and/or has dramatically elevated plasma glucose concentrations (>300–350 mg/dl), or an a1c ≥10–12%, insulin therapy should be strongly considered from the outset” [3]. |
| PubMedID- 22618776 | Msc infusion ameliorated hyperglycemia in rats with type 2 diabetes (t2d). |
| PubMedID- 21046527 | Aleglitazar, being developed by roche holding, is a dual agonist for ppargamma and pparalpha for the potential simultaneous treatment of hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 22238392 | Context: dapagliflozin, a selective sodium-glucose cotransporter 2 (sglt2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (t2dm) by increasing urinary glucose excretion, and weight loss is a consistent associated finding. |
| PubMedID- 23202932 | Chronic hyperglycemia in type 2 diabetes promotes oxidative stress and diabetic complications [1], and may even be involved in pathogenesis of the disease [2]. |
| PubMedID- 24721668 | Furthermore, patients who required medication typically used for treatment of hyperglycemia in type 2 diabetes (e.g. |
| PubMedID- 25905178 | hyperglycemia in type 2 diabetes is characterized by several pivotal abnormalities. |
| PubMedID- 26504840 | In 2013, chinese hospital association (cha) set up a systematic management program of hyperglycemia in inpatients with type 2 diabetes (t2d) admitted to top tertiary hospital to improve the care of inpatients with t2d in china and, in particular, to learn the profile of hypoglycaemia and associated factors. |
| PubMedID- 26207068 | Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. |
| PubMedID- 26207067 | Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. |
| PubMedID- 22203831 | Furthermore, the impairment of glp-1 secretion after meals could contribute to the pathogenesis of hyperglycemia in type 2 diabetes. |
| PubMedID- 24065793 | If correct, this would suggest that the str response may act to enhance the relative rate of glucose absorption and accentuate postprandial hyperglycemia in type 2 diabetes. |
| PubMedID- 21270909 | Recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes. |
| PubMedID- 23185996 | In contrast, macrovascular complications have been less affected by this intervention and seem to appear even before onset of hyperglycemia, particularly in patients with type 2 diabetes. |
| PubMedID- 23573479 | Male kk/ta mice spontaneously exhibit type 2 diabetes associated with hyperglycemia, glucose intolerance, hyperinsulinemia, mild obesity and microalbuminuria, conditions which are more severe than those found in the female (2-4). |